Paradigm change in first-line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma
E Borcoman, G Marret, C Le Tourneau - Cancers, 2021 - mdpi.com
Simple Summary Immunotherapy has made a breakthrough in the treatment of patients with
recurrent and/or metastatic head and neck squamous cell carcinoma in the second line …
recurrent and/or metastatic head and neck squamous cell carcinoma in the second line …
Viral vector-based therapeutic HPV vaccines
T Ji, Y Liu, Y Li, C Li, Y Han - Clinical and Experimental Medicine, 2024 - Springer
Replication-defective viral vector vaccines have several advantages over conventional
subunit vaccines, including potent antibody responses, cellular responses critical for …
subunit vaccines, including potent antibody responses, cellular responses critical for …
Systemic therapy for advanced cervical cancer: Leveraging the historical threshold of overall survival
E Paulino, AC de Melo, DAP de Andrade… - Critical Reviews in …, 2023 - Elsevier
Cervical cancer (CC) is a worldwide problem, especially in low-and middle-income
countries, where patients are often diagnosed with locally advanced disease. Until recently …
countries, where patients are often diagnosed with locally advanced disease. Until recently …
Current Status of Human Papillomavirus–Targeted Therapies Development in Head and Neck Cancer
JC Park, B Bertaux, J Park, S Park - JCO Precision Oncology, 2023 - ascopubs.org
PURPOSE While the incidence of smoking-related head and neck squamous cell carcinoma
(HNSCC) has been declining, that of human papillomavirus (HPV)–mediated HNSCC has …
(HNSCC) has been declining, that of human papillomavirus (HPV)–mediated HNSCC has …
The Role of P16, P53, KI-67 and PD-L1 Immunostaining in Primary Vaginal Cancer
Simple Summary To date, vaginal cancer is the only tumor entity of the female genital tract
without a practical guideline within the National Comprehensive Cancer Network (NCCN) …
without a practical guideline within the National Comprehensive Cancer Network (NCCN) …
[HTML][HTML] Combining PD-1/PD-L1 Inhibitors and HPV Vaccines Holds Promise in HNSCC
M Fares - 2021 - targetedonc.com
Research on combination therapies involving human papillomavirus (HPV)-targeted
vaccines and immunotherapies continues to expand in phase 2 and 3 trials in patients with …
vaccines and immunotherapies continues to expand in phase 2 and 3 trials in patients with …
[引用][C] The Role of P16, P53, KI-67 and PD-L1 Immunostaining in Primary Vaginal Cancer. Cancers 2023, 15, 1046
Background: To analyze clinical, pathological and immunohistochemical correlates of
survival in vaginal cancer patients. Methods: Retrospective analysis of primary vaginal …
survival in vaginal cancer patients. Methods: Retrospective analysis of primary vaginal …